Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

By S. Yusuf, S. Islam, C. Chow, S. Rangarajan, G. Dagenais, R. Diaz, Rajeev Gupta, Roya Kelishadi, R. Iqbal, Á. Avezum and 13 more. The Lancet, 2011

907 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Organizational Behavior and Human Resource Management, Surgery

View Paper: https://www.semanticscholar.org/paper/c5b538ba68de44a55f015525b65c25dde4220aaa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. George Davey Smith
2. K. F. Schulz
3. P. Ridker
4. I. Graham
5. L. Melvin
6. V. Basevi
7. Peter Libby
8. T. Ivanova

In Surgery

1. J. Armitage
2. George Davey Smith
3. R. Collins
4. M. Law
5. P. Ridker
6. I. Graham
7. Peter Libby
8. Massimo F. Piepoli

Citations in the corpus

• Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations (2013, background): “Third, secondary prevention, whichmay further reducemortality, ismakingmore headwayinimple-mentation in wealthier countries [28].”
• Interpretation of the evidence for the efficacy and safety of statin therapy. (2016, background): “China or India).(293) Across mainland Europe, in the Study of Health”